Latest Clinical Trials
Aytu BioPharma has developed an endotracheal respiratory catheter which its CEO says has “tremendous potential” in IPF, PAH, and other respiratory diseases.
When it comes to rare disorders, Israel—a New Jersey-sized nation of 9.3 million that’s made headlines this year for its highly successful coronavirus vaccination campaign—is clearly an emerging powerhouse.
Two important uses of the 6-MWT are pretreatment and posttreatment comparisons and predicting morbidity and mortality in patients with pulmonary hypertension
New York City’s Noah Greenspan, DPT, says early detection is key for pulmonary arterial hypertension (PAH), but the prognosis for PAH is improving.
Under COVID-19’s lingering shadow, the National Organization of Rare Disorders (NORD) has presented its 2021 Rare Impact Awards to 24 pharmaceutical firms, researchers, politicians, and nonprofit groups for their efforts over the past year on behalf of patients with such illnesses.
PAH Patient Perspectives
I live with pulmonary arterial hypertension (PAH), a progressive rare disease that is treated by addressing the symptoms only and not the disease.
In the summer of 2015, I had started to feel early symptoms of what would become a diagnosis of pulmonary arterial hypertension (PAH).
PAH Clinical Insights
Clinical researchers are emphasizing the value of exercise in alleviating the symptoms of some diseases, including pulmonary arterial hypertension (PAH).
Members of the general public generally recognize carbon monoxide (CO) as a toxic gas that can be lethal if a person is exposed to large quantities of it over a short period of time. CO poisoning is insidious because the gas itself is colorless, tasteless, and odorless, making it harder to detect. In a study…
Beta-blockers may have different effects in the early stages of pulmonary arterial hypertension than in later stages of the disease.
We discuss the challenges of treating pediatric patients with PAH, especially the scarcity of clinical data specific to children.
The progressive changes associated with PAH predispose patients to developing hemoptysis, especially when congenital heart disease is also present.
We explore the vast medical challenge of treating the combination of idiopathic pulmonary fibrosis and pulmonary hypertension successfully.
Rare Care Podcast
Noah Greenspan, DPT, founder of New York City’s Pulmonary Wellness & Rehabilitation Center, runs the nonprofit Pulmonary Wellness Foundation. In this interview, he talks about diagnosing and treating pulmonary arterial hypertension.
PAH Meeting Coverage